Three days after a single exposure to ozone, the mechanism of airway hyperreactivity is dependent on substance P and nerve growth factor.
Ozone causes persistent airway hyperreactivity in humans and animals. One day after ozone exposure, airway hyperreactivity is mediated by release of eosinophil major basic protein that inhibits neuronal M(2) muscarinic receptors, resulting in increased acetylcholine release and increased smooth muscle contraction in guinea pigs. Three days after ozone, IL-1β, not eosinophils, mediates ozone-induced airway hyperreactivity, but the mechanism at this time point is largely unknown. IL-1β increases NGF and the tachykinin substance P, both of which are involved in neural plasticity. These experiments were designed to test whether there is a role for NGF and tachykinins in sustained airway hyperreactivity following a single ozone exposure. Guinea pigs were exposed to filtered air or ozone (2 parts per million, 4 h). In anesthetized and vagotomized animals, ozone potentiated vagally mediated airway hyperreactivity 24 h later, an effect that was sustained over 3 days. Pretreatment with antibody to NGF completely prevented ozone-induced airway hyperreactivity 3 days, but not 1 day, after ozone and significantly reduced the number of substance P-positive airway nerve bundles. Three days after ozone, NK(1) and NK(2) receptor antagonists also blocked this sustained hyperreactivity. Although the effect of inhibiting NK(2) receptors was independent of ozone, the NK(1) receptor antagonist selectively blocked vagal hyperreactivity 3 days after ozone. These data confirm mechanisms of ozone-induced airway hyperreactivity change over time and demonstrate 3 days after ozone that there is an NGF-mediated role for substance P, or another NK(1) receptor agonist, that enhances acetylcholine release and was not present 1 day after ozone.
Department of Physiology & Pharmacology, Oregon Health & Science Univ., Portland, OR 97239, USA.
Kirsten C
KC
Verhein
Mehdi S
MS
Hazari
Bart C
BC
Moulton
Isabella W
IW
Jacoby
David B
DB
Jacoby
Allison D
AD
Fryer
D000393:Air Pollutants / Q000633:toxicity; D000818:Animals; D016535:Bronchial Hyperreactivity / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D016084:Bronchoconstriction / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000294:innervation / Q000503:physiopathology; D008297:Male; D008954:Models, Biological; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D064729:Neurokinin-1 Receptor Antagonists; D010126:Ozone / Q000008:administration & dosage / Q000633:toxicity*; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors / Q000502:physiology; D013373:Substance P / Q000502:physiology*; D013997:Time Factors; D014630:Vagus Nerve / Q000503:physiopathology
D000393:Air Pollutants; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D013373:Substance P; D010126:Ozone; D020932:Nerve Growth Factor